SAN DIEGO—Award presentations & artificial intelligence topped the list in the ACR Convergence 2023 Opening Session & Keynote Lecture on Nov. 11.
Special Interests in Rheumatology: What are your peers saying about laboratory testing, practice & workforce issues at ACR Convergence 2023?
ACR Convergence 2023 offers so much more than scientific sessions. If you have a special interest in a topic, this is the place to be. Consider these opportunities: Lab Tests Open Meeting Sunday, Nov. 12, 10–11 a.m. PST Location: Sapphire E Room, Hilton San Diego Bayfront Attendees interested in laboratory testing issues are invited to…
Expert to Weigh in on Top PsA Research
Science involves reading and writing as much as conducting experiments, says David S. Pisetsky, MD, PhD. No matter what discoveries are made in the lab, if they can’t be communicated well, how can they be used to advance the field and benefit patients? Dr. Pisetsky, the founding physician editor of The Rheumatologist, a professor of…
Getting Skin & Joint in the Game
In this session at ACR Convergence 2023 (15W112), Ursula Fearon, PhD, Christopher Ritchlin, MD, MPH, and Jose Scher, MD, will highlight recent work that describes key processes in the pathophysiology of psoriatic arthritis, including perturbations in immune and stromal cells and the microbiome. Watch for our article for a snapshot of what these experts have…
Your Invitation Here: Learn How Advocacy Can Help You & Your Practice
Learn how ACR staff and volunteers support the interests of the rheumatology community in public policy efforts related to Medicare reimbursement, step therapy reform, drug pricing, supporting the medical workforce and more.
Fellows in Training Learn & Network at ACR Convergence
PHILADELPHIA—The fellows-in-training (FIT) programs at ACR annual meetings are highly valued educational sessions that also offer a forum for fellows to meet and connect with trainees from other programs. Fellows who were not able to meet in person during the pandemic years, particularly those who were in their second or third year of training, welcomed…
The Effect of Upadacitinib on Bone Erosion in Patients with RA
Ho et al. found that upadacitinib may impede the progression of bone erosion in patients with RA. Additionally, bone scans of patients with limited exposure to conventional synthetic disease-modifying antirheumatic drugs showed bone erosion regression, which may result from upadacitinib’s inhibition of Janus kinase 1.
Peresolimab Promising for RA
Stimulating human programmed cell death protein 1 (PD-1), a checkpoint inhibitory receptor, with peresolimab may be a viable way to treat autoimmune diseases, according to a study by Tuttle et al. In the study, patients with active rheumatoid arthritis (RA) who were treated with peresolimab experienced greater improvements in disease activity than those who received placebo.
Sunny San Diego to Welcome ACR Convergence 2023
An in-person poster hall and networking lounges are among the highlights attendees can expect at ACR Convergence 2023 in San Diego, Nov. 10–15.
JAK Inhibitors vs. TNF Inhibitors: Understanding Infection Risks
Research from Choi et al. provides insights into the risk of infection in patients with rheumatoid arthritis (RA), comparing patients treated with Janus kinase inhibitors vs. tumor necrosis inhibitors. The most frequent infection was herpes zoster, with patients treated with JAK inhibitors having a significantly greater risk of herpes zoster infection than those treated with TNF inhibitors.
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 42
- Next Page »